Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Defining distinct molecular subtypes of esophageal adenocarcinoma for targeted therapy

EF 2022-23

Résumé
Esophageal cancer is one of the deadliest forms of cancer worldwide, with only 20% of patients surviving 5 years after diagnosis. The standard treatment regimen involves chemotherapy and radiation followed by surgical resection, but up to a third of patients do not respond to treatment, limiting survival and functional outcomes. This inconsistency in treatment response is in large part due to our currently limited understanding of the underlying biology of esophageal cancer. Current treatment treats it as a single disease, but there are likely many different subtypes of the cancer which respond differently to treatment. In fact, recent research has shown that the molecular biology of esophageal cancer is patient-specific, with different patients’ tumors having relatively few genetic elements in common. Using advanced genomics analysis of hundreds of tumor samples, our lab is focused on identifying and characterizing different molecular subtypes of esophageal cancer, with the goal of identifying new therapeutic targets for treatment based on subtype. Working with patient-specific tissues, the aim of this project is to identify candidate subtypes and identify correlations between these genetic subtypes and patient outcome data, including survival times and treatment response. This work will be accomplished using RNA sequencing, organoid models, and large-scale bioinformatics analysis. The outcomes of this project will enable us to better understand the variations in the biology of esophageal cancer, paving the way for development of targeted therapies for patients based on their tumor subtypes, and ultimately improving survival and functional outcomes for patients.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
490920
Name
Brar Karanbir S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Defining distinct molecular subtypes of esophageal adenocarcinoma for targeted therapy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Esophageal Cancer; Genome Sequencing; Molecular Subtyping; Organoid Models; Rna Sequencing; Targeted Therapy
Abstract
Esophageal cancer is one of the deadliest forms of cancer worldwide, with only 20% of patients surviving 5 years after diagnosis. The standard treatment regimen involves chemotherapy and radiation followed by surgical resection, but up to a third of patients do not respond to treatment, limiting survival and functional outcomes. This inconsistency in treatment response is in large part due to our currently limited understanding of the underlying biology of esophageal cancer. Current treatment treats it as a single disease, but there are likely many different subtypes of the cancer which respond differently to treatment. In fact, recent research has shown that the molecular biology of esophageal cancer is patient-specific, with different patients’ tumors having relatively few genetic elements in common. Using advanced genomics analysis of hundreds of tumor samples, our lab is focused on identifying and characterizing different molecular subtypes of esophageal cancer, with the goal of identifying new therapeutic targets for treatment based on subtype. Working with patient-specific tissues, the aim of this project is to identify candidate subtypes and identify correlations between these genetic subtypes and patient outcome data, including survival times and treatment response. This work will be accomplished using RNA sequencing, organoid models, and large-scale bioinformatics analysis. The outcomes of this project will enable us to better understand the variations in the biology of esophageal cancer, paving the way for development of targeted therapies for patients based on their tumor subtypes, and ultimately improving survival and functional outcomes for patients.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Brar, Karanbir S
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~